269 related articles for article (PubMed ID: 16728948)
1. Con: allogeneic transplantation in multiple myeloma.
van Rhee F
Clin Adv Hematol Oncol; 2006 May; 4(5):391-4. PubMed ID: 16728948
[No Abstract] [Full Text] [Related]
2. Pro: allogeneic transplantation in multiple myeloma.
Gahrton G
Clin Adv Hematol Oncol; 2006 May; 4(5):388-91. PubMed ID: 16728947
[No Abstract] [Full Text] [Related]
3. Clinical and molecular remission following reduced intensity conditioning and allogeneic transplantation in a patient with refractory multiple myeloma.
Dodero A; Perfetti V; Ciceri F; Corradini P
Haematologica; 2002 Dec; 87(12):ECR41. PubMed ID: 12495912
[No Abstract] [Full Text] [Related]
4. Controversy in multiple myeloma transplants: tandem autotransplants and mini-allografts.
Vesole DH; Simic A; Lazarus HM
Bone Marrow Transplant; 2001 Oct; 28(8):725-35. PubMed ID: 11781623
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes following myeloablative allogeneic transplantation for multiple myeloma compared to autologous transplantation and the impact of graft-versus-myeloma effect.
Khaled Y; Mellacheruvu S; Reddy P; Peres E; Mineishi S
Bone Marrow Transplant; 2009 Sep; 44(5):325-6. PubMed ID: 19204708
[No Abstract] [Full Text] [Related]
6. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
[TBL] [Abstract][Full Text] [Related]
7. The role of hematopoietic stem cell transplantation in Chronic Lymphocytic Leukemia.
Banerji V; Johnston JB; Seftel MD
Transfus Apher Sci; 2007 Aug; 37(1):57-62. PubMed ID: 17919979
[TBL] [Abstract][Full Text] [Related]
8. Single-centre experience with nonmyeloablative allogeneic stem cell transplantation in patients with multiple myeloma: prolonged remissions induced.
van Dorp S; Meijer E; van de Donk NW; Dekker AW; Nieuwenhuis K; Minnema MC; Petersen E; Schutgens R; Verdonck LF; Lokhorst HM
Neth J Med; 2007 May; 65(5):178-84. PubMed ID: 17519513
[TBL] [Abstract][Full Text] [Related]
9. Reversal of severe graft-versus-host disease after nonmyeloablative matched unrelated donor stem cell transplant by infusion of backup autologous peripheral blood stem cells.
Khan SA; Moreb JS
Bone Marrow Transplant; 2005 Aug; 36(3):267-8. PubMed ID: 15937501
[No Abstract] [Full Text] [Related]
10. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
11. [Recent progress in hematopoietic stem cell transplantation].
Shinagawa K
Gan To Kagaku Ryoho; 2006 Jun; 33(6):727-35. PubMed ID: 16770089
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation.
Ayuk F; Perez-Simon JA; Shimoni A; Sureda A; Zabelina T; Schwerdtfeger R; Martino R; Sayer HG; Alegre A; Lahuerta JJ; Atanackovic D; Wolschke C; Nagler A; Zander AR; San Miguel JF; Kröger N
Haematologica; 2008 Sep; 93(9):1343-50. PubMed ID: 18641030
[TBL] [Abstract][Full Text] [Related]
13. Hematopoietic stem cell transplantation in multiple myeloma.
Pant S; Copelan EA
Biol Blood Marrow Transplant; 2007 Aug; 13(8):877-85. PubMed ID: 17640590
[TBL] [Abstract][Full Text] [Related]
14. Graft-versus-myeloma after withdrawal of immunosuppression following allogeneic peripheral stem cell transplantation.
Libura J; Hoffmann T; Passweg J; Gregor M; Favre G; Tichelli A; Gratwohl A
Bone Marrow Transplant; 1999 Oct; 24(8):925-7. PubMed ID: 10516707
[TBL] [Abstract][Full Text] [Related]
15. Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma.
Bruno B; Sorasio R; Patriarca F; Montefusco V; Guidi S; Busca A; Scimé R; Console G; Milone G; Marotta G; Dominietto A; Giaccone L; Rotta M; Falda M; Bacigalupo A; Bosi A; Corradini P; Fanin R; Pollichieni S; Boccadoro M;
Eur J Haematol; 2007 Apr; 78(4):330-7. PubMed ID: 17331132
[TBL] [Abstract][Full Text] [Related]
16. Allografting or autografting for myeloma.
van Rhee F; Crowley J; Barlogie B
N Engl J Med; 2007 Jun; 356(25):2646-8; author reply 2646-8. PubMed ID: 17582078
[No Abstract] [Full Text] [Related]
17. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma.
El-Cheikh J; Michallet M; Nagler A; de Lavallade H; Nicolini FE; Shimoni A; Faucher C; Sobh M; Revesz D; Hardan I; Fürst S; Blaise D; Mohty M
Haematologica; 2008 Mar; 93(3):455-8. PubMed ID: 18287132
[TBL] [Abstract][Full Text] [Related]
18. The allogeneic dilemma.
Harousseau JL
Bone Marrow Transplant; 2007 Dec; 40(12):1123-8. PubMed ID: 17680016
[TBL] [Abstract][Full Text] [Related]
19. Allografting or autografting for myeloma.
Moreau P; Harousseau JL; Attal M
N Engl J Med; 2007 Jun; 356(25):2646-8; author reply 2646-8. PubMed ID: 17600892
[No Abstract] [Full Text] [Related]
20. Allogeneic bone marrow transplantation for multiple myeloma.
Ballester OF
Semin Oncol; 1993 Oct; 20(5 Suppl 6):67-71. PubMed ID: 8211218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
